Inspired by our previous study on Ru(II)-based compounds for the construction of a sensing platform toward detection of microRNA-185 (miR-185), we herein report new analytical platforms based on two additional Ru(II) compounds, <b>Ru 2</b> and <b>Ru 3</b>, with larger aromatic ring structures and richer hydrogen bond donor/acceptor sites in comparison to the previously reported <b>Ru 1</b>, as simultaneous detection agents for miR-221/222, which work together to promote the occurrence and development of breast cancer.
The set of miRNAs hsa-mir-146a, hsa-mir-93, hsa-mir-375, hsa-mir-205, hsa-mir-15a, hsa-mir-21, hsa-mir-20a, hsa-mir-503, hsa-mir-29c, hsa-mir-497, hsa-mir-107, hsa-mir-125a, hsa-mir-200c, hsa-mir-212, hsa-mir-429, hsa-mir-34a, hsa-let-7c, hsa-mir-92b, hsa-mir-33a, hsa-mir-15b, hsa-mir-224, hsa-mir-185 and hsa-mir-10b integrate a profile that critically regulates the expression of the mRNA coding for Smad7 in breast cancer.
Two miR-185 SNPs provided suggestive evidence of an inverse association with breast cancer risk (rs2008591, OR = 0.72 (95 % CI = 0.53-0.98, p value = 0.04) and rs887205, OR = 0.71 (95 % CI = 0.52-0.96, p value = 0.03), respectively) among African Americans.